VISION BIOSYSTEMS PROGESTERONE RECEPTOR PGR CLONE 16 by VISION BIOSYSTEMS INC.

Vision BioSystems Progesterone Receptor Clone 16 (PGR Clone 16) Mouse Monoclonal antibody is intended for laboratory use to qualitatively identify by light microscopy, progesterone receptor (PGR) antigen in sections of formalin fixed, paraffin embedded tissue. PGR Clone 16 specifically binds to the PGR antigen located in the nucleus of PGR positive normal and neoplastic cells.

PGR Clone 16 is indicated as an aid in the management, prognosis and prediction of therapy outcome of breast cancer. The clinical interpretation of any staining or its absence should be complemented by morphological studies using proper controls and should be evaluated within the context of the patient's clinical history and other diagnostic tests by a qualified pathologist.

Novocastra™ antibodies are intended for manual use. Origin™ antibodies are optimized for use with the Ventana® Medical Systems, NexES® and BenchMark™ Immunohistochemistry Staining Systems in combination with Ventana® Defection Kits. Bond™ Ready-to-Use Primary Antibodies are optimized for use on the Vision BioSystems Bond-max™ system.

Device Description

PGR Clone 16 is a monoclonal mouse antibody that detects a human progesterone receptor epitope located in the nucleus of PGR positive cells.

AI/ML Overview

This looks like a 510(k) premarket notification for an immunohistochemistry reagent, not a typical AI/ML-powered medical device. The provided text describes the device (Vision BioSystems Progesterone Receptor Clone 16), its intended use, and its substantial equivalence to a predicate device.

Therefore, the requested information about acceptance criteria, study data, sample sizes, ground truth, experts, and AI-specific performance metrics (like MRMC studies) are not typically found in this type of submission for a an IHC reagent. These details are much more relevant for diagnosing, detecting or predicting disease with AI/ML systems.

I cannot extract the detailed information requested in your prompt because it is not present in the provided document. The document describes a traditional in-vitro diagnostic device (an antibody for pathology) and not an AI/ML-based device that would have the kind of performance studies and statistical analyses you're asking for.

However, I can provide a general interpretation based on the nature of 510(k) submissions for such devices:

Likely "Acceptance Criteria" for such a device would relate to:

Analytical Performance:
- Specificity: The antibody should bind only to the progesterone receptor (PGR) antigen and not to other irrelevant antigens. This is typically assessed through staining of known positive and negative tissues.
- Sensitivity: The antibody should detect PGR wherever it is present in the tissue.
- Reproducibility/Repeatability: Consistent staining results when tested multiple times by the same operator or different operators, and across different lots of the reagent.
- Stability: The reagent maintains its performance characteristics over its shelf life.
Clinical Performance (in comparison to predicate):
- Concordance: The results obtained with the new device (PGR Clone 16) should be substantially equivalent (highly concordant) with those obtained using the legally marketed predicate device (DAKO Corporation Mouse Monoclonal Progesterone Receptor PgR 636) in terms of positive and negative staining, and often, the intensity and pattern of staining.

The "Study That Proves the Device Meets Acceptance Criteria" would fundamentally be:

A "Bridging Study" or "Comparative Study" against the predicate device. This involves testing a set of clinical tissue samples (often breast cancer tissues, given the intended use) with both the new device and the predicate device.
Internal Verification/Validation Studies: These are conducted by the manufacturer to establish the analytical performance characteristics mentioned above.

Given the limitations of the provided text, I can only fill in the table and address the other points based on what is typically done for such a device, rather than explicit details from this particular 510(k) summary.

1. Table of Acceptance Criteria and Reported Device Performance

Acceptance Criteria (Typical for IHC Reagent)	Reported Device Performance (Implied by 510(k))
Specificity: Detects only PGR antigen.	"PGR Clone 16 specifically binds to the PGR antigen located in the nucleus of PGR positive normal and neoplastic cells." (Stated in Indications for Use)
Sensitivity: Detects PGR when present.	"qualitatively identify by light microscopy, progesterone receptor (PGR) antigen in sections of formalin fixed, paraffin embedded tissue." (Implies adequate sensitivity)
Reproducibility: Consistent staining across runs/users/lots.	Not explicitly detailed in this summary, but a standard requirement for IVD validation.
Substantial Equivalence: Concordance with predicate device.	"PGR Clone 16 is substantially equivalent to DAKO Corporation Mouse Monoclonal Progesterone Receptor PgR 636." (Primary basis of 510(k) clearance)
Intended Use: Performs as an aid in breast cancer management, prognosis, and therapy prediction.	"PGR Clone 16 is indicated as an aid in the management, prognosis and prediction of therapy outcome of breast cancer." (Stated Intended Use)

2. Sample size used for the test set and the data provenance

Sample Size: Not specified in the provided text. For IHC antibody 510(k)s, comparison studies against a predicate typically involve tens to hundreds of clinical cases, covering a range of positive and negative expressions.
Data Provenance: Not specified. Would typically involve anonymized tissue samples from pathology archives, likely retrospective since it's a validation study against an existing predicate. Country of origin not specified.

3. Number of experts used to establish the ground truth for the test set and the qualifications of those experts

Number of Experts: Not specified. For a comparative study, results for both the candidate and predicate device would ideally be read by at least one, and often two or more, qualified pathologists. For concordance, disagreements might be resolved by consensus or a third expert.
Qualifications of Experts: Must be qualified pathologists ("evaluated by a qualified pathologist" is mentioned in the Intended Use, implying this for clinical interpretation). Typically board-certified pathologists with experience in breast pathology.

4. Adjudication method for the test set

Adjudication Method: Not specified. If multiple pathologists were involved in reading the comparative slides, common methods include consensus review, majority vote (e.g., 2 out of 3 agree), or an independent third pathologist for discordant cases.

5. If a multi-reader multi-case (MRMC) comparative effectiveness study was done, If so, what was the effect size of how much human readers improve with AI vs without AI assistance

MRMC Study: No. This is not an AI-powered device. It is a laboratory reagent (an antibody). MRMC studies, especially those comparing human readers with and without AI assistance, are not applicable here.

6. If a standalone (i.e. algorithm only without human-in-the-loop performance) was done

Standalone Performance: No. This is a manual or automated (with specific staining systems) laboratory reagent that requires interpretation by a human pathologist. There is no AI algorithm involved in its primary function of detecting the antigen.

7. The type of ground truth used (expert consensus, pathology, outcomes data, etc)

Ground Truth: For comparative studies, the "ground truth" is often established by:
- Predicate Device Results: The results from the legally marketed predicate device (DAKO PgR 636) would serve as the primary reference for comparison for the new device.
- Pathology Review/Expert Consensus: Confirmation of the presence/absence and classification of PGR status by qualified pathologists reviewing H&E (hematoxylin and eosin) stained slides and potentially the predicate IHC stain.
- Clinical Diagnosis/Outcomes: While specific outcomes data might not be the direct "ground truth" for assay performance, the clinical utility is linked to established correlations between PGR status and breast cancer management/prognosis/therapy outcome.

8. The sample size for the training set

Training Set Sample Size: Not applicable in the context of an antibody reagent. Antibodies are not "trained" like AI algorithms. They are developed and validated. The development process would involve extensive analytical testing on various tissues, but there isn't a "training set" in the AI sense.

9. How the ground truth for the training set was established

Ground Truth for Training Set: Not applicable. For antibody development, quality control (QC) references (known positive/negative tissues) are used to assess the binding characteristics, but this is part of analytical validation, not "training."

Summary

{0}------------------------------------------------

1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1

JAN 2 9 2007

510(k) SUMMARY

and the comments of the comments of the comments of the comments of

and the comments of the comments of

and the comments of the comments of the comments of the comments of the contraction of the contribution of the contribution of the contribution of the contribution of the fir

and the comments of the comments of

Date Prepared	August 25, 2006
510(k) Number
Submitter	Vision BioSystems, Inc.1833 Portola Rd.Ventura, CA 93003
Contact	Ron LagerquistDirector, Regulatory Affairs
Device Name	Vision BioSystems Progesterone Receptor Clone 16
Common/Usual/Classification Name	Progesterone ReceptorImmunohistochemistry Reagents and Kits
Device Description	PGR Clone 16 is a monoclonal mouse antibody thatdetects a human progesterone receptor epitopelocated in the nucleus of PGR positive cells.
Intended Use	PGR Clone 16 is intended for in vitro diagnostic usefor the qualitative detection of progesterone receptorin formalin-fixed paraffin embedded tissues. PGRClone 16 is indicated as an aid in the management,prognosis and prediction of therapy outcome ofbreast cancer within the context of the patient'sclinical history and other diagnostic tests evaluatedby a qualified pathologist.
Substantial Equivalence	PGR Clone 16 is substantially equivalent to DAKOCorporation Mouse Monoclonal ProgesteroneReceptor PgR 636

{1}------------------------------------------------

DEPARTMENT OF HEALTH & HUMAN SERVICES

Image /page/1/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo features a stylized caduceus, a symbol often associated with medicine and healthcare. The words "DEPARTMENT OF HEALTH & HUMAN SERVICES USA" are arranged in a circular fashion around the caduceus.

Public Health Service

Food and Drug Administration 2098 Gaither Road Rockville MD 20850

JAN 2 9 2007

Re: K062615

VISION Biosystems Inc.

C/O Ronald F. Lagerquist

Ventura, California 93003

1833 Portola Road

Trade/Device Name: Vision BioSystems Progesterone Receptor Clone 16 Regulation Number: 21 CFR 864.1860 Regulation Name: Immunohistochemistry Reagents and Kits Regulatory Class: Class II Product Code: MXZ Dated: August 25, 2006 Received: September 5, 2006

Dear Mr. Lagerquist:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050. This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

{2}------------------------------------------------

Page 2 -

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at (240) 276-0450. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (240) 276-3150 or at its Internet address http://www.fda.gov/cdrh/industry/support/index.html.

Sincerely yours,

Rafa Becker/

Robert L. Becker, Jr., MD, PhD Director Division of Immunology and Hematology Office of In Vitro Diagnostic Device Evaluation and Safety Center for Devices and Radiological Health

Enclosure

{3}------------------------------------------------

Page 3 -

. . . . . .

cc: HFZ-401 DMC

HFZ-404 510(k) Staff HFZ- 440 Division

and the comments of the comments of

11 - 11 - 11 - 11

{4}------------------------------------------------

Indications for Use

510(k) Number K062615

Device Name:

Vision BioSystems Progesterone Receptor Clone 16 (PGR Clone16)

Novocastra™ Lyophilized Mouse Monoclonal Antibody .
Novocastra™ Liquid Mouse Monoclonal Antibody
Novocastra™ Ready-to-Use Primary Antibody .
Origin™ Ready-to-Use Primary Antibody
Bond™ Ready-to-Use Primary Antibody

Indications for Use:

Prescription Use

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)

PAGE IF NEEDED)

Division Sigh-Off Concurrence of CDRH, Office of Device Evaluation (ODE)

Office of In Vitro Diagnostic Device Evaluation and Safety

510(k) K062615

Regulation Number and Section

§ 864.1860 Immunohistochemistry reagents and kits.

(a)
Identification. Immunohistochemistry test systems (IHC's) are in vitro diagnostic devices consisting of polyclonal or monoclonal antibodies labeled with directions for use and performance claims, which may be packaged with ancillary reagents in kits. Their intended use is to identify, by immunological techniques, antigens in tissues or cytologic specimens. Similar devices intended for use with flow cytometry devices are not considered IHC's.(b)
Classification of immunohistochemistry devices. (1) Class I (general controls). Except as described in paragraphs (b)(2) and (b)(3) of this section, these devices are exempt from the premarket notification requirements in part 807, subpart E of this chapter. This exemption applies to IHC's that provide the pathologist with adjunctive diagnostic information that may be incorporated into the pathologist's report, but that is not ordinarily reported to the clinician as an independent finding. These IHC's are used after the primary diagnosis of tumor (neoplasm) has been made by conventional histopathology using nonimmunologic histochemical stains, such as hematoxylin and eosin. Examples of class I IHC's are differentiation markers that are used as adjunctive tests to subclassify tumors, such as keratin.(2) Class II (special control, guidance document: “FDA Guidance for Submission of Immunohistochemistry Applications to the FDA,” Center for Devices and Radiologic Health, 1998). These IHC's are intended for the detection and/or measurement of certain target analytes in order to provide prognostic or predictive data that are not directly confirmed by routine histopathologic internal and external control specimens. These IHC's provide the pathologist with information that is ordinarily reported as independent diagnostic information to the ordering clinician, and the claims associated with these data are widely accepted and supported by valid scientific evidence. Examples of class II IHC's are those intended for semiquantitative measurement of an analyte, such as hormone receptors in breast cancer.
(3) Class III (premarket approval). IHC's intended for any use not described in paragraphs (b)(1) or (b)(2) of this section.
(c)
Date of PMA or notice of completion of a PDP is required. As of May 28, 1976, an approval under section 515 of the Federal Food, Drug, and Cosmetic Act is required for any device described in paragraph (b)(3) of this section before this device may be commercially distributed. See § 864.3.